Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

GU13-170

Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170.

Status: Closed to Accrual

Newly diagnosed metastatic prostate cancer subjects with bone metastases will be accrued to this stratified randomized 2-arm Phase II trial. Subjects will be randomized 1:2 to ADT or ADT with Radium-223 dichloride respectively.

  • Condition:
    • Prostate Cancer
    • Bone Metastases
    • Prostate Neoplasms
  • Intervention:
    • Drug: LHRH agonist/antagonist
    • Drug: Bicalutamide
    • Radiation: Radium-223 dichloride
  • Phase: Phase 2

For full description, see www.clinicaltrials.gov.

Read a news release about this trial.

Watch a video about this trial:

Project Manager: Donna Sullivan, dsullivan@hoosiercancer.org; (317) 634-5842, ext. 40.